Search results for: 'software as a service translation'

17 Jun 2021  |  North America  |  Market Research

Global Biologics Contract Development and Manufacturing Organizations Growth Opportunities

Asset Co-Development with Clinical-stage Biopharmaceutical Companies and Disruptive Technologies Present Future Growth Potential

Infographics

×

This study presents Frost & Sullivans overall market and segment-wise revenue forecasts of the global biologics contract development and manufacturing organizations (bio-CDMO) market. It also highlights key growth opportunities for bio-CDMO market participants based on the main evolution in their business models and strategic approaches, as well as...

27 Nov 2019  |  North America  |  Market Research

Global Contract Research Organization (CRO) Market, Forecast to 2024

Increased Technology Adoption in the Form of eClinical Solutions and Innovative Trial Designs is Expected to Transform the CRO Landscape

Infographics

×

Key Issues Addressed

Increased technology adoption in the form of eClinical solutions and innovative trial designs is expected to transform the CRO landscape. Owing to a constantly changing pharmaceutical landscape, the industry is expected to witness a moderate 4% to 5% growth in the next 5 to 7 years, to surpass $1.5 trillion by 2025. In coordination with the indust...

21 Aug 2020  |  Global  |  Market Research

Hybridization of Clinical Trial Designs Reviving Global CRO Market Post-pandemic, 2019–2024

Patient-centric and Safety-focused Logistical Solutions will Create New Growth Opportunities

Infographics

×

In this research deliverable, Frost & Sullivan’s analyst team offers a bold perspective on the post-pandemic growth opportunities for the global CRO market. With the increased threat of COVID-19 and world-wide lockdowns in effect, the contract research organization (CROs) market is seeing interruptions in ongoing clinical trials and delays of new t...

24 Jul 2020  |  North America  |  Market Research

Curative Oncology and Rare Disease Therapies Transforming the Global Biologics Market, 2020–2024

Strategic Collaborations with Specialty Bio-CDMOs will Continue to Drive Growth Opportunities in Antibody-drug Conjugates and Gene Therapies

Infographics

×

Key Issues Addressed

With this research service, Frost & Sullivans Transformational Health team provides critical insights into the global biologics industry highlighting the growth opportunities, market revenue segmentation, and technology trends influencing its growth. The global biologics market covered in this study includes 4 major segments – antibody therapies, r...

23 Oct 2020  |  North America  |  Market Research

Access to New Therapy Areas to Drive Major Growth in the Global Biosimilars Market, 2020–2026

Outsourced Manufacturing of the Complex Third Wave of Biosimilars to Spark New Growth Opportunities

Infographics

×

Key Issues Addressed

In this research service, the Transformational Health team at Frost & Sullivan provides critical insights into the global biosimilar industry, highlighting the key growth opportunities, market revenue forecasts, and trends that will influence the industry with the emergence of the third wave of biosimilars. The global third-wave biosimilars market ...

By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more compl...

The global life sciences industry is onto a rocking start with the surge in CEO confidence from US tax reforms, rollicking equity markets and strengthening the global economy. Healthcare digitization, democratization creating explosion in patient data, emergence of value-based reimbursement models, and healthcare consumerism shifting the risk from ...

05 Feb 2021  |  North America  |  Market Research

Shifting Spotlight from Product- to Value-based Outcomes Intensifies Growth in the US Real-world Evidence IT Solutions Market

Early-stage R&D and Commercial Applications Fuel the Growth Pipeline

Infographics

×

The US healthcare industrys transition to a patient-centric model is moving rapidly with focus on outcomes and value; however, drug prices have increased and pharmaceutical research and development (R&D) productivity is at its lowest. The healthcare industry and IT solutions providers are finding real-world evidence (RWE) as a potential solution to...

An increasing focus on biologics, genomics, and multi-omics; the adoption of digital technologies; and a shift to patient-centric models are transforming the life sciences industry. At the same time, the emergence of value-based models, R&D activities to treat complex diseases, and healthcare consumerism provide an impetus to precision medicine. Wi...